| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_630b360599ea5cf4b5bcbc0c6c0a3e2d |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1271 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-91 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
1983-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eb77ea7a48e2d8a221720981ad68837e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cad440df6f24c727e1ee818d252967e9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_541e1c1afbb4e4447439a0e2fc2cb9c7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_afef8929df8db0467b5944332a912e35
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f9b2c01248932d489318d5b0e118e5bb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c320c5f03167a4ff92671fae8e478e71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d5f9415f46f7103fa82bfb94cc9184a6 |
| publicationDate |
1985-04-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-S6067434-A |
| titleOfInvention |
Antitumor agent |
| abstract |
PURPOSE: To provide an antitumor agent capable of selectively transferring the toxin and carcinostatic agent to the cancer cells by the missile therapy, and having high remedying effect, by bonding a monoclonal antibody recognizing α- fetoprotein with the toxin or carcinostatic agent effective to tumor cells. n CONSTITUTION: The objective antitumor agent is produced by bonding (A) a monoclonal antibody capable of recognizing the α-fetoprotein(AFP) especially preferably existing at the surface of a cell membrane with (B) a toxin or a carcinostatic agent effective to tumor cells. The monoclonal antibody can be prepared by producing a hybridoma from the AFP originated from human placenta by conventional method, dyeing the hepatocarcinoma cerulein with the monoclonal antibody separated from the supernatant liquid of the hybridoma, and selecting the positive antibody. The toxin is bonded with the antibody protein by crosslinking method. The carcinostatic agent is preferably sealed in liposome, and the monoclonal antibody is bonded to the surface of the liposome. n COPYRIGHT: (C)1985,JPO&Japio |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-2635267-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-2222591-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-2222591-A |
| priorityDate |
1983-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |